AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00875485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Additional challenge dose
Description: If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
Study NCT02304887 — intervention group
Intervention type: DRUG
Intervention: Bis, SERM Teriparatide, Denosumab
Description: Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
Study NCT04635943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
Study NCT04381598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stevia rebaudiana bertoni
Description: Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
Study NCT03046095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Resistance Exercise
Description: Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
Study NCT03046095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immobilization
Description: During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
Study NCT03397394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered daily.
Study NCT00479817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 10mg/kg
Study NCT03816345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, CSF, tissue, stool and urine samples
Study NCT03816345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06794346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone
Description: women will receive 300mcg of transdermal testosterone in cream daily for six months
Study NCT06794346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal testosterone gel
Description: women will receive 300mcg of vaginal gel testosterone daily for six months
Study NCT06794346 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: women will receive both vaginal gel and transdermal cream placebo for six months
Study NCT06796192 — intervention group
Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 minutes after application.
Study NCT06796192 — intervention group
Intervention type: OTHER
Intervention: Visible Light Exposure - Untreated zone
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study NCT00479817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 3 mg/kg
Study NCT00479817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
Study NCT06796816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Vector Analysis (BIVA)
Description: Bioelectrical Impedance Vector Analysis (BIVA) both in total body mode (Total Body Water) and segmental mode. The device used is the BIA 101 Anniversary by Akern. The BIVA exam will be performed in total body and segmental modes.~For total body mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 4 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the right foot (metatarsal). The cable connected to your instrument will then be connected to the electrodes. After the instrument is switched on, the variables are read and then analysed. For segmental mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 8 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the left hand, 2 on the right foot (metatarsal) and 2 on the left foot.
Study NCT00479817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
Study NCT00479817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386 Placebo
Description: AMG 386 Placebo
Study NCT02414945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02414945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02414945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor infiltrating lymphocytes (TILs)
Study NCT02414945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Study NCT03150745 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3- Cervical Pap smears
Description: Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
Study NCT03150745 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colposcopic examination
Description: 0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination
Study NCT03150745 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Office hysteroscopy
Description: 0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
Study NCT04583215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired Associative Stimulation (PAS)
Description: On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
Study NCT04583215 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Paired Associative Stimulation (PAS)
Description: On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
Study NCT00682903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GuardianR
Description: As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
Study NCT04601259 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Orkla Corn Plaster with salicylic acid
Description: Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
Study NCT04601259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orkla Corn Protector
Description: Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
Study NCT00177294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
Study NCT00177294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
Study NCT00177294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: 16 sessions of interpersonal psychotherapy (IPT)
Study NCT00177294 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Monitoring
Description: 16 weeks of depression care management(DCM). No psychotherapy will be provided.
Study NCT03650894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV every 2 weeks
Study NCT03650894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg IV every 6 weeks.
Study NCT03650894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Oral bicalutamide 150mg (3 x 50mg tablets) daily
Study NCT03107221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Eating internet-based self-help programme
Description: An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
Study NCT03330054 — intervention group
Intervention type: DEVICE
Intervention: fundoscope
Description: Fundoscope for eye examination
Study NCT04060212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotic
Description: Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
Study NCT00421759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Insoles
Description: Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
Study NCT00708045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: Brain scan with imaging tracer to assess brain tumor metabolism
Study NCT01803100 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this trial
Study NCT06793384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based Cognitive Stimulation Therapy (VR-CST)
Description: In the VR-CST condition, participants wore a head-mounted display (HMD; model: DPVR P1 Pro Headset) for the themed activities in every session except sessions 1 and 14. In these two sessions, group physical activities (such as passing a ball from one participant to another) were conducted, so no HMDs were used. In other sessions, panoramic images (e.g., wet market) and videos (e.g., the neighborhood surroundings) prepared by the project team were mainly used, supplemented by 2-dimensional images /videos in which preparing panoramic images/videos was deemed impossible. Such a situation occurred in Session 5 (current affairs), in which news clips or captions from newspaper websites served as more appropriate content for discussion than self-created panoramic images/videos.
Study NCT03460639 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Active laser
Description: Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
Study NCT03460639 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
Study NCT06793384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cognitive Stimulation Therapy (Conventional CST)
Description: In the conventional CST group, 2-dimensional images/videos illustrating content identical to the VR-CST condition were displayed via tablet computers (see Table 2 for details) in which participants could manipulate the size of the image depicted or the pace of the videos with the help of the facilitator/therapy assistant.
Study NCT03460639 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Control group
Description: In this group, we will only induce fatigue.
Study NCT01653301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELAC RT
Description: Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost).
Study NCT01653301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX RT
Description: * Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~* Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost).
Study NCT01480362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith \& Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
Study NCT01480362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Therapy
Description: Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
Study NCT01596660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaina 0.5%
Description: Bupivacaina 0.5% 20cc
Study NCT04637724 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
Study NCT04637724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: 10 sessions of Anodal tDCS of the dorsolateral prefrontal cortex over a period of 5 consecutive days (two session a day). Each session includes the placement of two tDCS electrodes (anodal at left prefrontal area and cathodal above the vertex) and 20 mins of anodal prefrontal stimulation. The tDCS session is received two time a day with a 3-5 hours interveal betwen sessions.
Study NCT03540589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy specific vibration device
Description: It is a device that produces vibration
Study NCT03540589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: The distraction will be obtained through tablet with videos
Study NCT04252313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Studies have been conducted to assess the effects of sound and noise on neonatal stress. Recently, music is being used in neonatal units to improve physiological and behavioral outcomes (Harling et al, 2009). Of the few studies done on the effectiveness of music during circumcision is a randomized double-blinded controlled trial conducted by Joyce et al (2001): it found that some physiologic outcomes were significantly lower among the music group in comparison to the EMLA group. They concluded that there is preliminary evidence to support the efficacy of EMLA and music in pain management of newborn circumcision; however, more rigorous studies are warranted for conclusive results.
Study NCT01031316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nondisclosure of screening echocardiogram results
Description: Subjects will be randomized to nondisclosure of screening echocardiogram results.
Study NCT01031316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disclosure of screening echocardiogram results
Description: Subjects will be randomized to disclosure of screening echocardiogram results.
Study NCT04075890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
Study NCT03957421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aquatic exercise, land based exercise
Description: general warm up and cool down. general exercises and treadmill training at self-selected intensity.
Study NCT01596660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: 20 cc of saline solution 0.9%, to infiltrate each side.
Study NCT03112330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plasma rich platelet injection
Description: Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
Study NCT03112330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline nasal spray
Description: two puffs of isotonic saline nasal spray twice daily
Study NCT01054404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide 0.3 mg/kg
Study NCT01054404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (up to 5mL)
Study NCT03929991 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: To record social and clinical characteristics
Study NCT02547090 — intervention group
Intervention type: PROCEDURE
Intervention: The use of two attending surgeons during posterior spinal fusion
Description: Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
Study NCT01499459 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cell transplantation
Description: Every patient is given 1x106 MSCs per kg infused via peripheral vein.